Drug Profile
OXi 6197
Alternative Names: Oxi-6197Latest Information Update: 08 Feb 2007
Price :
$50
*
At a glance
- Originator Baylor University; OXiGENE
- Class Antineoplastics
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 08 Feb 2007 Discontinued - Preclinical for Solid tumours in USA (unspecified route)
- 01 Jun 2005 This compound is still in active development
- 15 Jul 2002 Preclinical trials in Solid tumours in USA (unspecified route)